Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mtb72f
- Development stage
- Unknown
- Lead developer
- Gates Medical Research Institute
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
**Mtb72F** is a recombinant fusion protein subunit vaccine candidate developed for the prevention of tuberculosis (TB). It is composed of regions from two *Mycobacterium tuberculosis* proteins: Mtb32 (a serine protease, Rv0125) and Mtb39 (a PPE family protein, Rv1196). Mtb72F is designed to stimulate strong cellular immune responses, primarily inducing CD4+ T cell proliferation and interferon-gamma (IFN-γ) production, leading to enhanced protection against TB. The vaccine has been shown to provide greater immunogenicity and protection in animal models compared to its individual components. Mtb72F has also been formulated as a DNA vaccine and in combination with adjuvants such as AS02 in clinical trials. Its main clinical development as a protein subunit vaccine has focused on use as a booster after BCG or as a primary vaccine, with particular relevance in immunocompromised patients. It is being tested both as a recombinant protein vaccine (Mtb72F/AS02) and as a DNA vaccine (pcDNA3.1-Mtb72F).
- Other names
- MTB72FMTB-72FMTB 72FMtb72F/AS02Mtb72F DNA vaccineMtb-72F DNA vaccineMtb 72F DNA vaccine
02
Targets
Mtb32A (Mycobacterium tuberculosis antigen Mtb32A)Mtb39A (Mycobacterium tuberculosis antigen Mtb39A)
Beyond the preview
Go deeper on mtb72f.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mtb72f.